Compare Costco Wholesale Corporation (COST) vs Moderna, Inc. (MRNA) Price & Performance

Costco (COST) trades at $944.32, down 0.88% on the day, with a bearish technical signal but strong fundamentals including consistent revenue growth to $275.24B in 2025 and a net income margin of 3.01%. Recent March sales surged 11.3% year-over-year, and the company raised membership fees for the first time in seven years, signaling pricing power. The stock is near its pivot point of $944, with support at $938 and resistance at $950.

The outlook remains positive due to robust membership renewal rates and expansion potential, though high valuation ratios like a P/E of 47.77 pose risks. Analyst consensus is strongly bullish with a $1,120 price target, but investors should monitor competitive pressures and macroeconomic headwinds that could impact consumer spending.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.